Ozempic vs Wegovy: Are They the Same Drug?

Research-informed explainer — last updated 2026-04-11

Yes — Ozempic and Wegovy are the same molecule, semaglutide, made by the same manufacturer. They differ in FDA-approved indication, maximum dose, titration schedule, and how insurance pays for them. Ozempic (up to 2 mg weekly) is approved for type 2 diabetes and cardiovascular risk reduction. Wegovy (2.4 mg weekly) is approved for chronic weight management. Understanding the distinction matters because it determines what your insurance will cover, what dose your prescriber can write, and whether a compounded version is safe to use.

What semaglutide actually is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a hormone your gut releases after eating, which signals the pancreas to release insulin, tells the liver to reduce glucose output, and slows stomach emptying. The result is lower blood sugar after meals and a strong reduction in appetite. Both effects made it valuable first in diabetes, then in obesity.

Novo Nordisk developed semaglutide and brought it to market under two brand names: Ozempic in 2017 for type 2 diabetes, and Wegovy in 2021 for chronic weight management. The FDA treats them as separate products with separate approvals because the indications, dosing, and clinical trial packages are different — even though the active ingredient is chemically identical.

How the doses differ, and why it matters

Ozempic is available in three maintenance doses: 0.5 mg, 1 mg, and 2 mg once weekly. Prescribers typically start patients at 0.25 mg for four weeks to reduce GI side effects, then step up. The 2 mg dose was added to the label in 2022 after trials showed additional glycemic benefit in patients who needed more aggressive A1c lowering.

Wegovy uses a higher maintenance dose — 2.4 mg weekly — and a longer titration schedule. Patients begin at 0.25 mg weekly and step up every four weeks over approximately 16 weeks before reaching the full dose. The slower ramp is designed to reduce the nausea, vomiting, and diarrhea that are more common at higher exposures.

The dose difference is clinically meaningful. The pivotal STEP 1 trial, published in the New England Journal of Medicine in 2021, tested semaglutide at 2.4 mg in adults with obesity but without type 2 diabetes. Participants lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group [1]. That magnitude of weight loss — roughly 33 pounds in a person starting at 220 pounds — is not achievable with the 1 mg dose used in earlier diabetes trials. The extra 0.4 mg relative to Ozempic's maximum dose is part of what produces the result.

At a glance

The clinical trial evidence behind each indication

The STEP 2 trial, also published in 2021, tested semaglutide 2.4 mg in adults who had both obesity and type 2 diabetes. Average body weight fell by 9.6% versus 3.4% with placebo — a meaningful result, though smaller than the 14.9% seen in STEP 1, likely because the metabolic effects of T2D blunt some of the weight response [3]. This trial was important because it established that the Wegovy dose also works in people with diabetes, bridging the two indications.

The SELECT trial, published in the New England Journal of Medicine in 2023, extended the evidence further. It enrolled over 17,000 adults with preexisting cardiovascular disease and overweight or obesity but without diabetes — and tested semaglutide 2.4 mg (the Wegovy dose) against placebo. Semaglutide reduced the rate of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% over a mean follow-up of nearly 40 months [2]. That finding was significant enough that the FDA added a cardiovascular risk reduction indication to Wegovy's label in 2024 — the same type of label that had previously belonged to Ozempic in the diabetes population.

Both drugs now carry cardiovascular risk reduction labeling, but for different patient populations: Ozempic's CV label applies to people with type 2 diabetes and established heart disease; Wegovy's applies to people with obesity or overweight and established heart disease, regardless of diabetes status.

The AACE comprehensive T2D management algorithms, co-authored by Washington University endocrinologist Janet McGill, MD, provide the clinical framework that helps prescribers position these agents within a treatment strategy. The algorithms prioritize GLP-1 receptor agonists for patients who need A1c lowering alongside cardiovascular or weight benefit, and specify which drug characteristics align with which patient priorities [6, 7]. In that framework, Ozempic and Wegovy are not interchangeable: the choice depends on whether the primary goal is glycemic control, weight loss, or cardiovascular risk reduction — or some combination.

Insurance coverage: the biggest practical difference

For most patients, insurance coverage — not clinical evidence — determines which drug they can access.

Ozempic is covered by the majority of commercial insurance plans and Medicare Part D for patients with a documented type 2 diabetes diagnosis. Prior authorization is still required in many plans, but approval rates are relatively high once the diagnosis is confirmed.

Wegovy has a more complicated coverage landscape. Commercial plans vary widely: some cover it with prior authorization, many do not. Medicare Part D historically excluded weight-loss drugs, and while the Treat and Reduce Obesity Act would change that, coverage for obesity pharmacotherapy under Medicare remains limited as of this writing. State Medicaid programs differ further. Patients paying out of pocket face a list price around $1,350 per month, though Novo Nordisk offers savings programs.

The practical result: some patients with obesity but without diabetes find it easier to access Ozempic off-label — because their plan covers it for diabetes even when they do not have the condition, or because a prescriber writes it for glycemic prevention — than to access Wegovy on-label for its approved indication. This is a policy problem, not a clinical one.

Ozempic prescribed off-label for weight loss

When a patient does not have type 2 diabetes but wants to use semaglutide for weight loss, prescribers sometimes write Ozempic off-label. This is legal — physicians may prescribe any approved drug for any indication they judge appropriate — but several issues follow.

First, the dose. Ozempic's maximum approved dose is 2 mg. Wegovy's weight-loss trials were done at 2.4 mg. An off-label Ozempic prescription for weight loss is almost always written at a dose lower than the one studied for that purpose.

Second, insurance. Off-label weight loss use of Ozempic is generally not covered, so the patient often ends up paying cash regardless of which brand is prescribed.

Third, monitoring and titration guidance. Wegovy's label includes a specific titration schedule optimized for weight management. Off-label use follows the diabetes dosing schedule, which may not be the best fit.

For patients who genuinely need weight management treatment, using Wegovy on-label — when coverage is available — is the more defensible path.

Compounded semaglutide: what the safety concerns are

During periods when both Ozempic and Wegovy were on the FDA shortage list (2022–2024), compounding pharmacies began producing semaglutide copies, often marketed directly to consumers and prescribed through telehealth platforms. Some of these products used semaglutide base (the salt form of the molecule) rather than semaglutide as the active pharmaceutical ingredient in the approved products.

The FDA has raised concerns about compounded semaglutide on multiple grounds. Compounded products are not FDA-approved and have not undergone the same manufacturing, purity, or stability testing as Ozempic and Wegovy. Reports of dosing errors, contamination, and adverse events prompted warnings. When the FDA removed Wegovy from its shortage list in 2024, compounding of the 2.4 mg formulation became legally impermissible under most circumstances.

For patients who encountered compounded semaglutide during the shortage period, the key takeaways are: the product may have had a different bioavailability profile than the branded drug, and side effect reports should be discussed with a prescriber, not assumed to represent how the branded medication would have behaved.

Where newer dual agonists fit in

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) targets both GLP-1 and GIP receptors. SURMOUNT-2, a 2023 trial in adults with both obesity and type 2 diabetes co-authored by Atlanta endocrinologist Bruce Bode, MD, found that tirzepatide 15 mg produced average weight loss of 15.7% — modestly exceeding semaglutide's effect in a similar population [5]. In head-to-head trials comparing the two molecules directly, tirzepatide has generally shown somewhat greater weight reduction.

The comparison puts the Ozempic vs. Wegovy question in perspective. The more consequential clinical question for many patients is not "which brand of semaglutide" but "semaglutide vs. tirzepatide" — a decision that also depends on insurance, side effect tolerance, A1c goals, and access. An endocrinologist familiar with both drug classes can help patients navigate these tradeoffs against their specific clinical profile.

Questions to ask your doctor or prescriber

• Do I have type 2 diabetes, prediabetes, or obesity without diabetes — and how does that determine which drug is appropriate?
• What is my insurance coverage for Ozempic vs. Wegovy, and will prior authorization be required?
• If Wegovy is not covered, is there a patient assistance program or savings card that applies to me?
• Would tirzepatide be a better fit for my combination of A1c and weight goals?
• What titration schedule will you use, and what GI side effects should I expect in the first few months?
• If I lose significant weight and maintain it, is this a lifelong medication or is there a plan for tapering?
• Are compounded semaglutide products from telehealth platforms safe alternatives if I cannot access the branded drugs?

The bottom line

Ozempic and Wegovy are the same molecule — semaglutide — made by the same company. They carry different FDA approvals, reach different maximum doses, and are covered differently by insurance. The clinical evidence is robust: at 2.4 mg, semaglutide produces weight loss that meets the threshold for meaningful obesity treatment and reduces cardiovascular events in people with obesity and established heart disease. At lower doses, it is effective for type 2 diabetes management and cardiovascular risk reduction in that population.

The practical advice: if your primary goal is weight loss and you do not have type 2 diabetes, Wegovy is the on-label product. If you have type 2 diabetes and need glycemic control, Ozempic is the indicated drug. If your prescriber offers you a compounded version, ask about the evidence base and why the branded product is not being considered. And if your insurance covers neither, an endocrinologist can walk you through prior authorization pathways, patient assistance programs, and whether a different drug class is a better fit for your situation.